U.S. Markets open in 4 hrs 50 mins

CLASS ACTION UPDATE for USX, CRBP and NTNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / April 18, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

U.S. Xpress Enterprises, Inc. (USX)

Class Period: Purchasers of common stock pursuant/and or traceable to the initial public offering completed in June 2018
Lead Plaintiff Deadline : May 10, 2019
Join the action: https://www.zlk.com/pslra-1/u-s-xpress-enterprises-inc-loss-form-2?prid=1171&wire=1

The complaint alleges that the Offering Documents failed to disclose that: (1) a shortage of trucks was negatively impacting U.S. Xpress's dedicated division; (2) (a) certain shipping patterns had been performing differently than expected and, as a result, (b) utilization, driver retention and hiring were being negatively affected, and as a result, (c) U.S. Xpress's dedicated accounts, including one large account, were being negatively impacted; and as a result, (d) U.S. Xpress's OTR division was providing continued support to the dedicated division; (3) (a) U.S. Xpress failed to stay informed regarding two large liability events; and as a result (b) U.S. Xpress's insurance claim expense was understated; and (4) U.S. Xpress's cost per mile for driver wages and independent contractors was exceeding the Company's internal expectations.

To learn more about the U.S. Xpress Enterprises, Inc. class action contact jlevi@levikorsinsky.com.

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Class Period: November 14, 2016 - February 28, 2019
Lead Plaintiff Deadline : May 13, 2019
Join the action: https://www.zlk.com/pslra-1/corbus-pharmaceutical-holdings-inc-loss-form?prid=1171&wire=1

About the lawsuit: Throughout the class period, Corbus Pharmaceuticals Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about the Corbus Pharmaceuticals Holdings, Inc. class action contact jlevi@levikorsinsky.com.

Nutanix, Inc. (NTNX)

Class Period: Class A shares purchased between March 2, 2018 and February 28, 2019
Lead Plaintiff Deadline : May 28, 2019
Join the action: https://www.zlk.com/pslra-1/nutanix-inc-loss-form?prid=1171&wire=1

The complaint concerns whether the Company and its executives violated federal securities laws by making false and/or misleading statements about its investments in growth and its maintenance of high profit margins.

On February 28, 2019, Nutanix announced its second quarter fiscal 2019 results and reported third quarter guidance that was below analysts' expectations. Management acknowledged that "inadequate marketing spend for pipeline generation and slower than expected sales hiring" were the reasons for the weak guidance. On this news, Nutanix's share price fell from $50.09 per share on February 28, 2019 to a closing price of $33.70 on March 1, 2019.

To learn more about the Nutanix, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com